Figure 1 - uploaded by Taha Alqahtani
Content may be subject to copyright.
5: Structure of FLT3 receptor -FLT3 consists of five immunoglobulin-like domains in the extracellular region, a transmembrane domain (TM), a juxtamembrane domain (JM), and two intracellular tyrosine kinase domains (TKD) linked by a kinase insert.
Source publication
In approximately 23% of AML patients, Fms-like tyrosine kinase 3 (FLT3)
contains a gain-of-function, internal tandem duplication (ITD) mutation that is
associated with an unfavourable prognosis. FLT3 is therefore seen as a
promising therapeutic avenue for AML and as a result, a more complete
understanding of its function and signalling may lead to...
Citations
... FLT3 activation causes autophosphorylation and the start of many signaling pathways [143]. The migration of signaling molecules to functional FLT3 by binding to particular phosphorylated tyrosine residues in the intracellular domain of FLT3 initiates signaling mechanism [144]. FLT3 activation regulates differentiation proliferation and hematopoietic progenitor cell survival. ...
Cellular and stromal components including tumor cells, immune cells, mesenchymal cells, cancer-linked fibroblasts, and extracellular matrix, constituent tumor microenvironment (TME). TME plays a crucial role in reprogramming tumor initiation, uncontrolled proliferation, invasion and metastasis as well as response to therapeutic modalities. In recent years targeting the TME has developed as a potential strategy for treatment of cancer because of its life-threatening functions in restricting tumor development and modulating responses to standard-of-care medicines. Cold atmospheric plasma, oncolytic viral therapy, bacterial therapy, nano-vaccine, and repurposed pharmaceuticals with combination therapy, antiangiogenic drugs, and immunotherapies are among the most effective therapies directed by TME that have either been clinically authorized or are currently being studied. This article discusses above-mentioned therapies in light of targeting TME. We also cover problems related to the TME-targeted therapies, as well as future insights and practical uses in this rapidly growing field.
